Search - tctmd.com

Displaying 41 - 60 of 101

Sort: Relevancy | Date

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Daily News

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

Michael O'Riordan

August 17, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

L.A. McKeown

May 19, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Daily News

Critical Limb Ischemia During COVID: Lessons for Care and Clinical Trials

L.A. McKeown

April 26, 2021

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Daily News

Features of Complex CAD Carry Progressive Risk in PCI, Registry Confirms

Caitlin E. Cox

October 08, 2020

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

News

Drug-Coated Balloons for CAD: Some International Consensus

L.A. McKeown

May 27, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

L.A. McKeown

March 09, 2020

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

L.A. McKeown

January 29, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Daily News

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

Todd Neale

January 15, 2020

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

Advertisement

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

Critical Limb Ischemia During COVID: Lessons for Care and Clinical Trials

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Features of Complex CAD Carry Progressive Risk in PCI, Registry Confirms

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Drug-Coated Balloons for CAD: Some International Consensus

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

Lutonix BTK Studies: Below-the-Knee Challenges Linger

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content